BIONIK Laboratories Corp. Quarterly report pursuant to Section 13 or 15(d)

Warrants

9 Months Ended

Dec. 31, 2020

9. Warrants

The following is a continuity schedule of the Company’s common share purchase warrants:


		Weighted
		Average
	Number of	Exercise
	Warrants	Price
Outstanding and exercisable, March 31, 2019	288,517	40.27
Expired	(163,483)	(38.91)
Outstanding and exercisable, March 31, 2020	125,034	20.07
Expired	(2,667)	(37.50)
Outstanding and exercisable December 31, 2020	122,367	19.69

During the nine months ended December 31, 2020, 2,667 warrants expired in accordance with their terms.

Common share purchase warrants

The following is a summary of common share purchase warrants outstanding as of December 31, 2020.

The weighted-average remaining contractual term of the outstanding warrants was 1.57 years.